Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

prorenoate potassium

Known as: potassium prorenoate 
The potassium salt form of prorenoate, a steroidal aldosterone antagonist with potassium-sparing diuretic activity. Prorenoate antagonizes the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
We have previously reported our studies on glucocorticoid (GC) effects on Na+ influx in vascular smooth muscle (VSM) cells. We… Expand
1993
1993
We have previously demonstrated that receptors to both mineralocorticoids (MC) and glucocorticoids (GC) exist in the arterial… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
1989
1989
This study investigated the anti-mineralocorticoid potency and haemodynamic effects of a series of mineralocorticoid antagonists… Expand
1985
1985
A 3-month dose range finding study in preparation for a 2-yr carcinogenicity study of potassium prorenoate (SC-23992), a steroid… Expand
  • table I
  • table I
  • table I
  • table IV
  • table V
1982
1982
1 After repeated single daily doses, the aldosterone antagonists prorenoate potassium and spironolactone were compared with… Expand
1981
1981
The dose ratio approach was used to define the steady‐state relative potency of the competitive mineralocorticoid antagonists… Expand
1979
1979
Two new aldosterone antagonists, K-prorenoate [potassium 3(17 beta-hydroxy-6 beta, 7 beta-methylen-3-oxo-4-androsten-17 alpha-yl… Expand
1979
1979
To investigate the possible direct effect of two aldosterone antagonists (Canrenoate-K and Prorenoate-K) upon mineralocorticoid… Expand
1976
1976
1 The pharmacodynamic profile of single oral doses of prorenoate potassium (40 mg) and spironolactone (100 mg), as judged by… Expand
1975
1975
The potency of single doses of a new aldosterone antagonist, prorenoate, in reversing the renal effects of the synthetic… Expand